Recent developments and future perspectives in the systemic treatment of metastatic colorectal cancer
Systemic treatment of metastatic colorectal cancer is increasingly being tailored towards the individual clinical situation of the patient. In particular, the k-ras mutation status as a predictive marker for the therapeutic efficacy of epidermal growth factor receptor (EGFR)-antibodies is now routinely implemented in clinical practice to define the subgroup of patients benefiting most from treatment. This review discusses the current status of treatment strategies using intermittent and maintenance therapy concepts based on recent clinical trials. Furthermore, the conflicting data on the use of the monoclonal EGFR-antibody cetuximab in combination with oxaliplatin containing chemotherapy derived from recent phase III trials are summarised and discussed. Finally, first clinical data on the use of monoclonal antibodies against novel targets (i.e. Hepatocyte Growth Factor and Insulin-like Growth Factor-1 Receptor) are presented.